{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
BioLife Solutions, Inc.
BioLife Solutions, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
BioLife Solutions, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, priced at $26.52, has experienced notable volatility over the past year. Technical indicators suggest a generally positive outlook, while performance comparisons with the S&P 500 reveal mixed results over different time frames.
BioLife Solutions Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
BioLife Solutions, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock outperformed the S&P 500 today and over the past week, with various technical indicators showing bullish signals. This activity suggests growing interest and confidence in the company’s prospects.
Is BioLife Solutions, Inc. technically bullish or bearish?
As of October 3, 2025, BioLife Solutions, Inc. shows a bullish technical trend with strong weekly and monthly MACD indicators, despite some mixed signals from longer-term indicators and a recent outperformance against the S&P 500.
Is BioLife Solutions, Inc. technically bullish or bearish?
As of October 3, 2025, BioLife Solutions, Inc. shows a bullish technical trend with strong weekly and monthly indicators, though mixed signals suggest caution due to some bearish trends in KST and On-Balance Volume, despite outperforming the S&P 500 recently.
Is BioLife Solutions, Inc. technically bullish or bearish?
As of September 10, 2025, BioLife Solutions, Inc. shows a mildly bullish trend supported by strong weekly indicators, despite mixed signals from monthly MACD and daily moving averages, while underperforming the S&P 500 over the past year and three years.
Is BioLife Solutions, Inc. overvalued or undervalued?
As of February 28, 2022, BioLife Solutions, Inc. is considered overvalued and has a risky valuation grade due to poor financial metrics, including a high Price to Book Value of 3.20, negative EV to EBIT and EV to EBITDA ratios, and underperformance compared to the S&P 500, particularly with a 3-year return of 13.67% versus 70.41% for the index.
Is BioLife Solutions, Inc. technically bullish or bearish?
As of June 20, 2025, the technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and daily moving averages, despite a bullish weekly RSI, with mixed signals from Dow Theory and underperformance compared to the S&P 500.
Is BioLife Solutions, Inc. overvalued or undervalued?
As of February 28, 2022, BioLife Solutions, Inc. is considered overvalued and risky due to negative performance metrics, including a P/E ratio of NA, an EV to EBITDA of -1053.88, and a year-to-date decline of 17.72%, contrasting sharply with its peers and the S&P 500's positive performance.
Who are in the management team of BioLife Solutions, Inc.?
As of March 2022, the management team of BioLife Solutions, Inc. includes Mr. Raymond Cohen (Independent Chairman), Mr. Michael Rice (President and CEO), Mr. Andrew Hinson (Independent Director), and Mr. Joseph Schick (Independent Director). They oversee the company's strategic direction and operations.
What does BioLife Solutions, Inc. do?
BioLife Solutions, Inc. develops and markets biopreservation tools for cells, tissues, and organs in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $24 million and has a market cap of approximately $1.03 billion.
How big is BioLife Solutions, Inc.?
As of Jun 18, BioLife Solutions, Inc. has a market capitalization of $1,033.98 million, with net sales of $105.55 million and a net profit of -$11.30 million over the latest four quarters. The balance sheet shows shareholder's funds of $348.91 million and total assets of $404.34 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
